Articles tagged "HLA antibodies"

2022 American Transplant Congress
Local Intragraft Humoral Immune Response in Chronic Lung Allograft Dysfunction
E. Miyamoto¹, S. C. Juvet², D. Vosoughi², J. Wang², J. Al-Refaee², T. Daigneault², A. Duong², S. Moshkelgosha², S. Keshavjee², K. Tinckam², A. Chruscinski³, D. Hwang⁴, T. Martinu²
¹Tenri Hospital Japan, University Health Network Canada, Nara, Japan, ²University Health Network, Toronto, ON, Canada, ³Multi-Organ Transplantation, University Health Network, Toronto, ON, Canada, ⁴Sunnybrook Health Science Centre, Toronto, ON, Canada
*Purpose: Donor HLA-specific antibody (DSA) and antibody against self-antigens (self-antigen antibody) can cause injury and lead to chronic lung allograft dysfunction (CLAD) after lung transplantation…
2022 American Transplant Congress
Which is More Important for Predicting De Novo DSA Production, B Cell Epitope (EPLET) or T Cell Epitope (PIRCHE) Analysis ?
T. Kobayashi¹, T. Tomosugi², S. Sakamoto², S. Ashimine¹, K. Iwasaki¹, M. Niemann³, E. Spierings⁴, Y. Miwa¹, M. Okumura¹, K. Ishiyama¹, A. Takeda², N. Goto², S. Narumi², Y. Watarai²
¹Aichi Medical University School of Medicine, Nagakute, Japan, ²Nagoya Daini Red Cross Hospital, Nagoya, Japan, ³PIRCHE AG, Berlin, Germany, ⁴UMC Utrecht, Utrecht, Netherlands
*Purpose: De novo donor-specific antibodies (dnDSA) can cause chronic ABMR, resulting in poor prognosis. Recently, mismatch at B cell epitope level, i.e. EPLET mismatch, has…
2022 American Transplant Congress
Early Clinical Complications Following HLA-Incompatible Living Donor Kidney Transplantation
J. D. Motter¹, K. Jackson¹, A. Massie¹, J. Garonzik-Wang², D. Segev¹
¹Johns Hopkins University, Baltimore, MD, ²University of Wisconsin-Madison, Madison, WI
*Purpose: Incompatible living donor kidney transplant recipients (ILDKTr) require desensitization to facilitate transplantation across donor-specific antibody (DSA); however, this substantial upfront immunosuppression may result in…
2021 American Transplant Congress
Relationship Between %dd-cfDNA, MMDx Molecular Diagnoses, and Donor-specific Antibody in the Trifecta Study
P. F. Halloran¹, L. G. Hildago², J. Reeve¹, Z. Demko³, A. Prewett³, P. Billings³, J. Truong⁴, P. Vander Horn⁴, &. Trifecta Study Group⁵
¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²University of Wisconsin, Madison, WI, ³Natera Inc., San Carlos, CA, ⁴One Lambda Inc., West Hills, CA, ⁵., ., AB, Canada
*Purpose: The Trifecta Study is a prospective multicenter investigator-initiated trial to evaluate the relationship between %dd-cfDNA and molecular biopsy findings at the time an indication…
2021 American Transplant Congress
Higher Calcineurin Inhibitor Levels Associate with Graft Outcomes in Kidney Recipients with De Novo Donor-specific Antibodies of Either Hla Class I or II
M. Béland, S. De Serres
Nephrology, CHU de Québec- Université Laval, Québec, QC, Canada
*Purpose: The development of de novo anti-HLA donor specific antibodies (dnDSA) is associated with poorer outcomes in kidney transplant recipients. We and other previously reported…
2021 American Transplant Congress
Athena – Effect of Primary Immunosuppression on Development of De Novo Donor Specific Antibodies within First Year After Kidney Transplantation
W. Arns¹, A. Philippe¹, V. Ditt¹, I. A. Hauser¹, F. Thaiss¹, C. Sommerer¹, B. Suwelack¹, A. Finkel², C. Schiedel², D. Dragun¹, B. Nashan¹
¹ATHENA, Study Group, Germany, ²Novartis Pharma GmbH, Nuremberg, Germany
*Purpose: The ATHENA trial [NCT01843348] investigated safety and efficacy of everolimus combined with cyclosporine A [EVR/CsA] or tacrolimus [EVR/TAC] vs. tacrolimus plus mycophenolic acid [MPA/TAC]…
2021 American Transplant Congress
Non-HLA Antibodies and Eplet Mismatches in Cases with Histological Picture of Antibody-Mediated Rejection with and without HLA Donor-Specific Antibodies
M. Crespo¹, L. Llinás², D. Redondo², C. Butler³, J. Gimeno⁴, M. Pérez-Sáez², A. Buxeda², C. Arias², M. Folgueiras², S. Sanz², N. Valenzuela³, E. E. Reed³, J. Pascual²
¹Nephrology and Kidney Transplantation, Hospital del Mar, Barcelona, Spain, ²Nephrology, Hospital del Mar, Barcelona, Spain, ³UCLA Immunogenetics Center, UCLA, Los Angeles, CA, ⁴Pathology, Hospital del Mar, Barcelona, Spain
*Purpose: Correlation between antibody-mediated rejection (ABMR) and HLA donor-specific antibodies (DSA) is strong but imperfect in kidney transplant (KT) recipients, raising the possibility of other…
2021 American Transplant Congress
Lung Transplant Recipients Developing Early DSAs are Characterized by a Shift Towards Memory B Cells Directly After Transplantation
S. Christoph¹, A. Hitz¹, R. Bellmàs Sanz¹, J. Kühne¹, B. Wiegmann², F. Ius², J. Salman², E. Chichelnitskiy¹, T. Siemeni², W. Sommer³, A. Haverich², G. Warnecke³, C. Falk¹
¹Institute of Transplant Immunology, MHH, Hannover, Germany, ²Department of Cardiothoracic, Transplant and Vascular Surgery, MHH, Hannover, Germany, ³Department of Cardiac Surgery, University Hospital Heidelberg, Heidelberg, Germany
*Purpose: After lung transplantation (LTx), the development of early donor HLA-specific antibodies (eDSA) is associated with antibody-mediated rejection (AMR) and poor graft survival. Since 2013,…
2021 American Transplant Congress
The Importance of Persistent and Recurrent T Cell Mediated Rejection in Tacrolimus Treated Renal Transplant Recipients
C. Rampersad¹, I. W. Gibson², D. N. Rush¹, D. Pochinco³, P. E. Birk⁴, A. Goldberg⁴, T. Blydt-Hansen⁵, M. Karpinski¹, J. Shaw¹, J. Ho¹, P. W. Nickerson¹, C. Wiebe¹
¹Department of Medicine, University of Manitoba, Winnipeg, MB, Canada, ²Department of Pathology, University of Manitoba, Winnipeg, MB, Canada, ³Shared Health Services Manitoba, Winnipeg, MB, Canada, ⁴Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, MB, Canada, ⁵Department of Pediatrics, University of British Columbia, Winnipeg, MB, Canada
*Purpose: Optimal follow-up after treatment for T-cell mediated rejection (TCMR) is not well-established. We sought to identify the prevalence and clinical associations of repeated TCMR…
2021 American Transplant Congress
Utility of Screening-Bead Assay in Post-Transplant Testing of Donor-Specific Antibodies (DSA) and Antibody-mediated Rejection (ABMR) in Renal Allografts
A. Agrawal¹, E. Dijke², A. Murray³, P. Campbell³
¹Transplant Nephrology, Mayo Clinic, Rochester, MN, ²Lab. Medicine and Pathology, University of Alberta Hospital, Edmonton, AB, Canada, ³Division of Nephrology, Dept. of Medicine, University of Alberta Hospital, Edmonton, AB, Canada
*Purpose: ABMR is a major cause of poor long-term graft survival. Though post-transplant monitoring of HLA DSAs can aid in risk stratification and optimizing immunosuppression,…